论文部分内容阅读
目的 地尔硫 (合心爽 )临床Ⅱ期试验研究 ,观察合心爽对肿瘤病人放疗不良反应治疗效果 ,评价口服合心爽的抗辐射效果。方法 采用肿瘤病人下半身照射试验模型 ,观察病人60 Coγ射线放疗后临床症状、外周血白细胞和血小板数及外周血染色体畸变率。结果 合心爽明显降低 2 2例放射治疗病人的食欲减退、腹泻、呕吐的发生率 ;与对照组比较 ,合心爽组的外周血白细胞总数和血小板总数在照射后 30d中总体水平上均有较好的恢复 ;染色体畸变率降低 ,按染色体畸变率估计 ,未治疗组患者全血的总平均吸收剂量为 1 5 2Gy ,而合心爽给药组仅为 0 86Gy。结论 该实验条件下 ,口服合心爽能减轻肿瘤病人放疗不良反应的发生程度。
Destination Sulfuricillin (co-heart Shuang) clinical phase Ⅱ trial study, observe the combined treatment of cancer patients adverse reactions radiotherapy effect, evaluation of oral co-heart Shuang radiation effect. Methods The experimental model of lower body irradiation in cancer patients was used to observe the clinical symptoms, the number of leucocytes and platelets in peripheral blood and the chromosome aberration rate in peripheral blood after 60 Co γ -ray radiotherapy. Results Hexin Shu obviously reduced the incidence of loss of appetite, diarrhea and vomiting in 22 radiotherapy patients. Compared with the control group, the total number of leukocytes and the total number of platelets in Hexinxin group were significantly higher than those in the control group Better recovery; chromosome aberration rate decreased, according to the estimated rate of chromosomal aberrations, untreated group of patients with a total average absorbed dose of 15g 2Gy, and the heart Xin Shuang treatment group was only 0 86Gy. Conclusion Under the experimental conditions, oral co-heart cool can reduce the incidence of adverse reactions of radiotherapy in cancer patients.